Effects of aleglitazar on cardiovascular risk factors in patients with stage 3 chronic kidney disease and type 2 diabetes
Herz, Matthias, Malmberg, Klas, Hanefeld, Markolf, Ruilope, Luis, Lincoff, A. Michael, Viberti, Giancarlo, Mudie, Nadejda, Urbanowska, Teresa, Reigner, Sylvie MeyerVolume:
231
Language:
english
Journal:
Atherosclerosis
DOI:
10.1016/j.atherosclerosis.2013.07.015
Date:
December, 2013
File:
PDF, 57 KB
english, 2013